Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.15
Bid: 12.10
Ask: 12.20
Change: -0.20 (-1.62%)
Spread: 0.10 (0.826%)
Open: 12.35
High: 12.35
Low: 12.05
Prev. Close: 12.35
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive Results POLB001 LPS Human Challenge Trial

2 Mar 2023 07:00

RNS Number : 6481R
Poolbeg Pharma PLC
02 March 2023

Poolbeg Pharma Plc


Positive Results from POLB 001 LPS Human Challenge Trial

Strong potential for POLB 001 to be a blockbuster treatment for severe influenza

Key Highlights

· POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines

· POLB 001 treatment exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo

· Trial results demonstrate expected utility in severe influenza and other acute inflammatory conditions

2 March 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a leading infectious disease focused biopharmaceutical company, announces the data readout from the bacterial lipopolysaccharide ('LPS') human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from severe influenza and other acute inflammatory conditions. POLB 001 was shown to be safe and well tolerated and had a potent effect in systemic and localised inflammatory response in a dose dependent manner.


About the LPS Challenge Trial

A total of 36 healthy volunteers aged 18 to 55 were enrolled and completed the trial. Subjects treated with POLB 001 exhibited a marked reduction in multiple markers of systemic and localised inflammation compared with placebo. p38 MAPK target engagement within circulating blood cells caused a substantial ablation of blood cytokines which are synonymous with cytokine release syndrome ('CRS') common in severe influenza, patients receiving CAR T cell treatment and other acute inflammatory conditions.


Systemic Inflammatory Response

The typical LPS-induced rise in plasma cytokine levels (TNF-α, IL-6, and IL-8) decreased between 57-81% across all cytokines in subjects treated with 70 mg or 150 mg POLB 001 (all highly significant P values


POLB 001 was shown to have the following dose dependent effects:

- blunted the LPS associated rise in heart rate across all dose groups (P

- reduced body temperature and C-reactive protein ('CRP') levels, a clinically used nonspecific marker of inflammation

- target engagement causing a dose dependent reduction in p38 phosphorylation activation status in white blood cells


Localised Inflammatory Response

POLB 001 infiltration into inflamed tissues blocked localised cytokine release and reduced invasion of tissue damaging inflammatory cells as reflected by:

- complete ablation of tissue damaging neutrophil accumulation within the inflamed tissue

- LPS-induced rise in intermediate monocytes (inflammatory mediators) was substantially lower in subjects treated with 70 mg or 150 mg POLB 001

- a highly significant reduction in TNF-α in subjects treated with 150 mg POLB 001 of 65.1% (P


Virtual Company presentation


Jeremy Skillington, PhD, Chief Executive Officer, David English, VP of Business Development and key opinion leader Derek Gilroy, PhD, Professor of Immunology at University College London, will provide a live presentation via the Investor Meet Company platform on Thursday 2 March 2023 at 10am. Click here to register.


The presentation is open to analysts and all existing and potential shareholders. Investors can sign up to Investor Meet Company for free and add to meet Poolbeg Pharma plc here. The presentation and recording will be available on the Company's website after the event here.


Jeremy Skillington, PhD, Chief Executive Officer, Poolbeg Pharma, said: "Together these data indicate POLB 001 reaches all cells and tissues where p38 MAPK is expressed, shutting down inflammation and silencing multiple aspects of overactivated inflammation unlike many anti-inflammatory drugs that target a single immune pathway.


POLB 001 blocks inflammation both locally and systemically and in a manner that suggests efficacy in treating life-threatening infections such as severe influenza or the CRS associated with other acute inflammatory conditions. POLB 001 has the potential to be an effective treatment in a wide range of inflammatory syndromes that present serious and life-threatening complications for patients. Due to our parallel clinical programs with POLB 001 we are particularly excited that these results support continued clinical investigation in both indications, and that we can share this positive data with potential Pharma partners ahead of schedule."


Derek Gilroy, Ph.D, Professor of Immunology at University College London, said: "The COVID-19 pandemic, more than anything in recent memory, has shown how bereft we are of the medicines needed to treat infections, and stop our immune system from killing us. With such pandemics increasing in frequency, it's only a matter of time before we face yet another crisis.


Poolbeg Pharma has risen to this challenge. POLB 001 has shown substantial promise in dampening the key players of harmful inflammation in both blood and tissues, acting where the immune system can do harm. These exciting data, and safety profile, support a role for POLB 001 beyond infectious diseases into treating a range of acute, aggressive immune responses."


About POLB 001 and the LPS Human Challenge Trial

POLB 001 is a small molecule immunomodulator for the treatment of cytokine release syndrome (CRS) related conditions such as severe influenza and other acute inflammatory conditions. POLB 001 selectively inhibits overwhelming inflammation in viral infections, such as influenza, while leaving the necessary immune functions intact to fight the infection. This contrasts with other immunomodulatory approaches, such as steroids, which affect both beneficial and damaging immune responses. Due to its mode of action it is strain agnostic and unaffected by seasonal variants which is a significant advantage over treatments available on the market. In addition, as a shelf stable oral drug it is an ideal stock piling candidate for both seasonal and pandemic outbreaks. Therefore, POLB 001 has the potential to be a transformational treatment for patients and to become a leading severe influenza treatment.


Cytokines, originally intended to optimise immunity, when overexpressed can sweep throughout the body re-programming white blood cells causing tissue damage, shutting down circulation and other essential organs leading to death; a process called septic shock and in certain circumstances cytokine storm or cytokine release syndrome (CRS). Such excessive cytokine responses can be seen in diseases such as severe influenza and in response to chimeric antigen receptor T cell therapy (CAR T cell) treatment of cancers. Poolbeg continues to evaluate POLB 001's potential in additional indications to fully unlock the potential value of the molecule.


p38 MAP kinase (p38 MAPK) is a master regulator of immunity, ubiquitously expressed in all white blood cells where it is poised to unleash inflammation. Poolbeg's clinical approach, inhibiting p38 MAP kinase hypothesised that it's a prime suspect in driving the cytokine storm and its consequences. This has now been demonstrated as a concept in a human clinical model of infectious disease and endotoxin mediated inflammation administering LPS as the endotoxin to healthy volunteers. LPS is a bacterial product that mimics infection and is used to capture the hallmarks of both local and systemic inflammation typical of a cytokine storm in humans, but in a safe, controlled and quantifiable manner - it's one step removed from the infected critical care patient. The trial was conducted at the Centre for Human Drug Research (CHDR) in the Netherlands with Principal Investigator Dr Matthijs Moerland.


- Ends -


Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O'Connell, CFO


+44 (0) 207 183 1499

finnCap Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)


+44 (0) 207 220 0500

Singer Capital Markets (Joint Broker)

Phil Davies, Sam Butcher


 +44 (0) 207 496 3000

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist


+353 (0) 1 679 6363

Optimum Strategic Communications

Mary Clark, Nick Bastin, Vici Rabbetts 


+44 (0) 208 078 4357


About Poolbeg Pharma


Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in prevalent and emerging infectious diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal.


The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.


With its initial assets from hVIVO plc (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza and other acute inflammatory conditions (POLB 001) which produces a highly significant reduction in p38 MAP kinase driven cytokines in a clinical setting; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing two Oral Delivery Programmes and is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline.


For more information, please go to or follow us on Twitter and LinkedIn @PoolbegPharma.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Date   Source Headline
17th Jun 20248:38 amRNSResult of AGM
9th May 20247:00 amRNSAnnual Report & AGM Notice
1st May 20247:00 amRNSSignificant POLB 001 Patent Granted in USA
30th Apr 20247:02 amRNSAppointment of Joint Broker
30th Apr 20247:01 amRNSOption Agreement to Acquire Orphan Drug Candidate
30th Apr 20247:00 amRNSResults for the year ended 31 December 2023
29th Apr 20247:00 amRNSTR-1: Notification of major holdings
22nd Feb 20247:00 amRNSDirector/PDMR Shareholding
19th Feb 20241:42 pmRNSDirector Share Purchase
15th Feb 20247:00 amRNSBoard Role Change and Launch of EIP
17th Jan 20247:00 amRNSFurther data shows POLB001 potential in cancer CRS
20th Dec 20237:00 amRNSRSV AI Drug Candidate Analysis Update
11th Dec 20237:00 amRNSPOLB 001 Data Presented at ASH
30th Nov 20237:00 amRNSDirectorate Change
21st Nov 20237:00 amRNSImmunomodulator II patent granted in Japan
16th Nov 20237:00 amRNSPOLB 001 LPS Trial Data to be Presented at IUIS
9th Nov 20237:00 amRNSFormer Amryt Pharma Leadership Team join Poolbeg
3rd Nov 20237:05 amRNSPOLB001 Data to be Presented at ASH Annual Meeting
1st Nov 20237:00 amRNSPOLB 001 Oncology Programme Update Meeting
26th Oct 20237:00 amRNSSAB Endorses Influenza Drug Targets
17th Oct 20237:00 amRNSPoolbeg Partners with a Nasdaq-Listed Biopharma
29th Sep 20237:00 amRNSFavourable Conclusion of Patent Opposition
20th Sep 20237:00 amRNSImmunomodulator I Patent Portfolio Strengthened
19th Sep 20237:00 amRNSImmunomodulator I Patent Opposition Withdrawal
13th Sep 20237:00 amRNSInterim results for the six months to 30 June 2023
29th Jun 20237:00 amRNSAI led programme identifies influenza drug targets
22nd Jun 20237:00 amRNSOral Vaccine Programme Moves Forward
24th May 20237:00 amRNSBoard Appointment
11th May 20232:27 pmRNSResults of Annual General Meeting
12th Apr 20237:00 amRNSAnnual Report & AGM Notice
30th Mar 20237:00 amRNSResults for the year ended 31 December 2022
10th Mar 20237:00 amRNSNotification of Major Holdings
9th Mar 20233:51 pmRNSNotification of Major Holdings
8th Mar 20237:00 amRNSPOLB 001 patent portfolio strengthened
2nd Mar 202311:05 amRNSSecond Price Monitoring Extn
2nd Mar 202311:00 amRNSPrice Monitoring Extension
2nd Mar 20237:00 amRNSPositive Results POLB001 LPS Human Challenge Trial
16th Jan 20237:00 amRNSStrategic expansion of POLB 001 into oncology
9th Jan 20239:05 amRNSSecond Price Monitoring Extn
9th Jan 20239:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSPositive Initial Data Analysis in POLB 001 Trial
22nd Dec 202210:48 amEQSPoolbeg Pharma identifies new RSV drug candidates
21st Dec 20227:00 amRNSPoolbeg identifies novel RSV drug candidates
15th Dec 20229:49 amEQSPoolbeg Pharma makes 'interesting addition to existing collaboration'
14th Dec 20227:00 amRNSMetabolic diseases oral delivery licence signed
12th Dec 20222:05 pmRNSSecond Price Monitoring Extn
12th Dec 20222:00 pmRNSPrice Monitoring Extension
12th Dec 202212:00 pmEQSPoolbeg Pharma receives initial results from human challenge clinical study
12th Dec 20227:00 amRNSPOLB 001 LPS human challenge trial completed
29th Nov 20227:00 amRNSInfluenza AI model build completed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.